Off‐label dosing of long‐acting injectable cabotegravir and rilpivirine during pregnancy: A case study with therapeutic drug monitoring
British Journal of Clinical Pharmacology · 2026-04 · 92 (4) · 1232-1236
DOI: 10.1002/bcp.70424 ↗Kurz gefasst
Fallbericht in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 16.12.2025. Verfasst von Natella Rakhmanina und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Children's National Hospital, Washington, District of Columbia, USA. Hauptthemen laut MEDLINE: Rilpivirine, Pyridones, HIV Infections, Pregnancy Complications, Infectious. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 13 Literaturangaben.
Abstract (Originalsprache)
We report individualized off‐label monthly use of a high dose of long‐acting intramuscular cabotegravir/rilpivirine (CAB/RPV = 600 mg/900 mg) co‐administered preconceptionally and throughout pregnancy with subcutaneous lenacapavir to a young woman with perinatally acquired HIV, multiple comorbidities, and class III obesity. Therapeutic drug monitoring for CAB and RPV was performed throughout the pregnancy and postpartum. At 7 weeks gestation, the plasma CAB and RPV C troughs were 16 (2.58 mg/L) and 9 (0.11 mg/L) times above the respective protein adjusted (PA)‐IC 90 . From 7 to 32 weeks of gestation, plasma CAB and RPV C troughs decreased to 1.28 and to 0.08 mg/L, respectively, but remained above PA‐IC 90 for both drugs. After receiving one monthly high‐dose CAB/RPV injection after delivery at 7 weeks postpartum, the plasma CAB and RPV C troughs were 4.02 and 0.19 mg/L, 56% and 73% higher than at 7 weeks of gestation. Despite a decrease in cabotegravir (50%) and rilpivirine (27%) concentrations between first and third trimesters, plasma exposures remained above therapeutic thresholds and viral load
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, Children's National Hospital, Washington, District of Columbia, USA.
- Department of Pediatrics, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA.
- Technical Strategies and Innovation, Elizabeth Glaser Pediatric AIDS Foundation, Washington, District of Columbia, USA.
- Center for Health Outcomes Research and Delivery Science, Children's National Research Institute, Children's National Hospital, Washington, DC, USA.
- Great Ormond Street Institute of Child Health, University College London, London, UK.
- Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA.
ORCID-Profile: Natella Rakhmanina
Zitieren
APA
Rakhmanina, N., Unternaher, J., Williams, T., Ryan, K. J., Walker, K., Acosta, E. P., Van Den Anker, J., & Scott, R. K. (2026). Off‐label dosing of long‐acting injectable cabotegravir and rilpivirine during pregnancy: A case study with therapeutic drug monitoring. British Journal of Clinical Pharmacology, 92(4), 1232-1236. https://doi.org/10.1002/bcp.70424
Vancouver
Rakhmanina N, Unternaher J, Williams T, Ryan KJ, Walker K, Acosta EP, et al. Off‐label dosing of long‐acting injectable cabotegravir and rilpivirine during pregnancy: A case study with therapeutic drug monitoring. British Journal of Clinical Pharmacology. 2026;92(4):1232-1236. doi:10.1002/bcp.70424
BibTeX
@article{Rakhmanina2026,
author = {Rakhmanina, Natella and Unternaher, Justin and Williams, Tierra and Ryan, Kevin J and Walker, Kedria and Acosta, Edward P and Van Den Anker, John and Scott, Rachel K},
title = {Off‐label dosing of long‐acting injectable cabotegravir and rilpivirine during pregnancy: A case study with therapeutic drug monitoring},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
volume = {92},
number = {4},
pages = {1232--1236},
doi = {10.1002/bcp.70424}
}
EUVIMED